Article content
MISSISSAUGA, Ontario — MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX), a global leader in teledermatology, is pleased to announce that, in connection with the Private Placement (the “Financing”), the $250,000 first tranche closing of which was announced in its Press Release dated July 14, 2022, it has applied to the TSX Venture Exchange for an extension of a further 30 days price protection in order to complete subscriptions for up to a total of $4 million. Further Closings, will be subject to receipt of subscriptions and a number of other conditions, including, without limitation, the receipt of all relevant regulatory and Stock Exchange approvals or acceptances.
Article content
The Financing is a non-brokered Private Placement to accredited investors of up to $4 million by issuance of up to 80 Convertible Loan Notes, each with a face value…
